• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-09

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin probe for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell or tissue samples. It is suited to immunofluorescence staining, flow cytometry carbohydrate analysis, and glycobiology workflows, but should not be used as a general non-carbohydrate probe or outside the stated storage and stability conditions.

• Dasatinib Monohydrate: From Kinase Blockade to Translation

  2026-09-09

  A translational perspective on how Dasatinib Monohydrate can connect imatinib-resistant BCR-ABL inhibition with resistance biology, neutrophil extracellular traps, and advanced tumor models.

• PP 2 (AG 1879): Src Signaling Beyond Cancer

  2026-09-08

  PP 2 (AG 1879) is a potent Src family kinase inhibitor with applications spanning cancer research, immunology, and vascular signaling. This article explains how a recent arterial study changes the interpretation of Src inhibition and provides a concentration-aware workflow for mechanistic assays.

• From Metabolomic Signatures to Mechanism

  2026-09-08

  A translational framework for converting burn-associated metabolic findings into testable pathway hypotheses using the DiscoveryProbe™ Metabolism-related Compound Library.

• FITC-Concanavalin A (ConA) Guide

  2026-09-07

  FITC-Concanavalin A (ConA) Conjugate provides a direct fluorescent approach for detecting accessible α-D-glucose and α-D-mannose residues on cell surfaces in microscopy and flow cytometry workflows. It is intended for carbohydrate-focused assays, not non-glycan targets, and should be used under the specified light-protected storage conditions.

• Mycophenolic Acid: Metabolic Control of Immunity

  2026-09-07

  A translational framework for using Mycophenolic acid as a dehydrogenase inhibitor in standardized whole-blood immunometabolism studies, with mechanistic context, validation priorities, handling guidance, and strategic limitations.

• PRINT: RNA-Mediated Safe-Harbor Transgene Insertion

  2026-09-05

  Zhang and colleagues introduce PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus through target-primed reverse transcription. The study shows that separately delivered protein-encoding and template RNAs can support multikilobase insertion in cultured primary human cells, offering a mechanistically distinct alternative to DNA-break repair and viral delivery.

• RNA Clean and Concentrator Kit for IVT RNA

  2026-09-04

  The RNA Clean and Concentrator Kit streamlines cleanup of transcription products before analytical assays, RNA delivery studies, and formulation workflows. Its membrane-based format separates RNA from nucleotides, enzymes, salts, and short oligonucleotides while supporting both single- and double-stranded RNA applications.

• DAMGO Workflows for µ-Opioid Receptor Research

  2026-09-04

  DAMGO provides a selective way to activate µ-opioid receptors while separating receptor-specific signaling from the broader effects of morphine. This guide translates its biochemical, ex vivo, and mouse-model utility into practical workflows for pain circuitry, opioid tolerance, and mechanical hypersensitivity studies.

• Demethyleneberberine in Neurodegeneration: Review Insights

  2026-09-03

  The reference paper presents Demethyleneberberine (DMB), a berberine metabolite, as a mechanistically plausible neuroprotective candidate that may coordinate antioxidant, anti-inflammatory, mitochondrial, and metabolic responses. Its value is hypothesis-generating: the review integrates evidence around NF-κB, MAPK, AMPK, oxidative stress, and monoamine oxidase-B while highlighting the need for direct pharmacokinetic and disease-model validation.

• Cyanine 3-dCTP for Reliable DNA Labeling

  2026-09-03

  A scenario-based guide to using Cyanine 3-dCTP (SKU B8159) for direct enzymatic labeling of DNA and cDNA, PCR, Nick Translation, and in situ hybridization workflows. It addresses assay interpretation, polymerase compatibility, reagent handling, optimization, and practical vendor-selection criteria without treating fluorescent nucleic-acid labeling as a substitute for direct viability measurements.

• Dorsomorphin 2HCl: Reading AMPK Causality

  2026-09-02

  Dorsomorphin 2HCl is an AMPK inhibitor that can test whether metabolic protection is genuinely AMPK-dependent. This article presents a pathway-aware framework for interpreting pharmacological inhibition across liver, BMP, iron, and osteogenesis models.

• Protease Inhibitor Cocktail: EDTA-Free Workflow Guide

  2026-09-02

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolysis during cellular protein extraction and protease-sensitive assays, including Western blotting, co-immunoprecipitation, and kinase workflows. Its EDTA-free format is useful when divalent cations must remain available, but DMSO tolerance, assay interference, and cell-line sensitivity should be verified experimentally.

• 10058-F4: From c-Myc Dimerization to TERT

  2026-09-01

  A translational framework for using 10058-F4 to connect c-Myc-Max disruption with apoptosis, acute myeloid leukemia research, prostate cancer models, and TERT chromatin regulation in human pluripotent stem cells.

• BMS 309403: A Causal Assay Strategy for FABP4

  2026-09-01

  BMS 309403 is a potent FABP4 inhibitor for dissecting lipid-driven inflammation and foam-cell biology. This guide translates the SERCA2–CaN/FoxO1/FABP4 findings into practical assay decisions for cardiovascular and metabolic disease research.

8416 records 1/562 page Next 12345 下5页 Last page